If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)
Rezvoglar ™ (insulin glargine-aglr) injection
3 mL (100 units/mL)
This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.
Is the formulation of Rezvoglar™ (insulin glargine‑aglr) and Basaglar® (insulin glargine) the same?
Rezvoglar and Basaglar are insulin glargine 100 units/mL products that have the same formulation.
Formulations of Rezvoglar and Basaglar
The inactive ingredients used in the formulation of Rezvoglar™ (insulin glargine‑aglr) 100 units/mL are the same as those in Basaglar® (insulin glargine) 100 units/mL (Excipients Contained in Rezvoglar and Basaglar Prefilled Pens).1,2
Inactive Ingredient |
Rezvoglar |
Basaglar |
Zinca, mcg/mL |
30 |
30 |
Metacresol, mg/mL |
2.7 |
2.7 |
Glycerinb, mg/mL |
17 |
17 |
Hydrochloric acid 10% |
For pH adjustmentc |
|
Sodium hydroxide 10% |
For pH adjustmentc |
|
Water for Injection, USP |
QS to 3 mL |
|
Abbreviations: Basaglar = Basaglar® (insulin glargine) 100 units/mL; QS = quantum sufficit; Rezvoglar = Rezvoglar™ (insulin glargine‑aglr) 100 units/mL; USP = United States Pharmacopeia.
aTo provide zinc ion.
b100% glycerin is used.
cThe pH is approximately 4.
Enclosed Prescribing Information
References
1Rezvoglar [package insert]. Indianapolis, IN: Eli Lilly and Company; 2024.
2Basaglar [package insert]. Indianapolis, IN: Eli Lilly and Company; 2021.
3Data on file, Eli Lilly and Company and/or one of its subsidiaries.
Date of Last Review: February 11, 2025